GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.
Research output: Contribution to journal › Article
Glucagon-like peptide-1 (GLP-1)-based therapy is a novel treatment for type 2 diabetes. It is executed either by GLP-1 mimetics or by dipeptidyl peptidase-IV inhibitors. In type 2 diabetes, the two strategies reduce hemoglobin A(1c) by 0.6% to 1.1% from baseline levels of 7.7% to 8.5%. They are efficient both in monotherapy and in combination with metformin or thiazolidinediones. Both treatments are well tolerated with low risk of hypoglycemia.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Journal||Current Diabetes Reports|
|Publication status||Published - 2007|